Glaukos Submits NDA for Epi-On CLX Candidate episode artwork

EPISODE · Jan 8, 2025 · 5 MIN

Glaukos Submits NDA for Epi-On CLX Candidate

from Eyewire News: The Podcast · host Eyewire News

Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Glaukos Submits NDA for Epi-On CLX Candidate

0:00 5:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 5 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on January 8, 2025.

What is this episode about?

Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!